On February 21, 2020, the Board of Directors (the “Board”) of PDS Biotechnology Corporation (the “Company”) appointed Kamil Ali-Jackson, Esq., as a director and new member of the
Board, effective February 21, 2020. Upon joining the Board, Ms. Ali-Jackson will also become a member of the Board’s Audit Committee (the “Audit Committee”). Following the appointment of Ms. Ali-Jackson, the Audit Committee will consist of
Stephen Glover, Kamil Ali-Jackson, and Gregory Freitag, J.D., CPA, with Mr. Freitag serving as the chair of the Audit Committee and its designated financial expert.
Kamil Ali-Jackson, Esq., age 60, has more than 30 years of experience as legal counsel in the life sciences industry with public and private specialty pharmaceutical, biotech and biopharmaceutical
companies. Ms. Ali-Jackson has extensive domestic and international experience with strategic alliances, drug development and commercialization collaborations and M&A transactions. Ms. Ali-Jackson is the co-founder of Aclaris Therapeutics, Inc.
and has served as its Chief Legal Officer since its inception in 2012. Ms. Ali-Jackson also serves as Chief Compliance Officer and Corporate Secretary of Aclaris. In addition, since 2013, Ms. Ali-Jackson has served as Chief Legal Officer of
NeXeption II, LLC and its affiliates. From 2014 to 2015, Ms. Ali-Jackson served as Chief Legal Officer of Ralexar Therapeutics, Inc. (formerly known as Alexar Therapeutics Inc.). Previously, Ms. Ali-Jackson served as legal counsel and as a
licensing business executive for a number of pharmaceutical companies, including Merck & Co. Inc., Dr. Reddy’s Laboratories Ltd. and Endo Pharmaceuticals, Inc. Ms. Ali-Jackson received her Juris Doctorate from Harvard Law School and Bachelor of
Arts in politics from Princeton University. Ms. Ali-Jackson was a 2011 Philadelphia Business Journal Woman of Distinction winner. Ms. Ali-Jackson has served on several nonprofit boards and is currently on the board of Rosemont College, a private
liberal arts college located in Pennsylvania.
There are no arrangements or understandings between Ms. Ali-Jackson and any other persons pursuant to which she was chosen as a director of the Company. There are no family relationships between
Ms. Ali-Jackson and any of the Company’s directors, executive officers, or persons nominated or chosen by the Company to become a director or executive officer. Ms. Ali-Jackson is not a party to any current or proposed transaction with the Company
for which disclosure is required under Item 404(a) of Regulation S-K.
On February 21, 2020, Ms. Ali-Jackson was granted an option to purchase 9,000 shares of the Company’s common stock at an exercise price of $1.31 per share, which was the closing price of the
Company’s common stock on the Nasdaq Capital Market on the date of grant. The option will vest in three equal annual installments of 3,000, each following the date of grant, subject to Ms. Ali-Jackson’s continuous service.